Twin Presentations Position Merck, GSK PD-1 Inhibitors As Endometrial Cancer Rivals

Merck & Co., Inc.’s PD-1 inhibitor Keytruda (pembrolizumab) may stand to benefit from its already leading position in cancers affecting women with new data in front-line endometrial cancer that set up stiff competition between it and relative newcomer GSK plc’s PD-1 inhibitor, Jemperli (dostarlimab).

Merck announced 27 March the presentation of data from the Phase III NRG-GY018 trial of Keytruda combined with standard-of-care carboplatin/paclitaxel chemotherapy versus chemotherapy alone in patients with first-line advanced or...